Saxagliptin
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
Saxagliptin (DB06335): Type 2 Diabetes Mellitus — No Repurposing Prediction Available
One-Sentence Summary
Saxagliptin is a selective dipeptidyl peptidase-4 (DPP-4) inhibitor used in the management of type 2 diabetes mellitus. This evidence pack contains no TxGNN repurposing predictions for this drug, and two critical data fields — mechanism of action and UK regulatory safety information — are missing. A full repurposing evaluation cannot be completed until these gaps are remediated.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Type 2 Diabetes Mellitus (DPP-4 inhibitor class — clinical knowledge; not captured in evidence pack) |
| Predicted New Indication | Not available — no TxGNN prediction generated |
| TxGNN Prediction Score | Not available |
| Evidence Level | L5 (no studies retrieved; model prediction not generated) |
| UK Market Status | Not recorded in evidence pack (0 authorisations returned) |
| Number of Marketing Authorisations | 0 (as per evidence pack — see note below) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
No repurposing prediction is present in this evidence pack, so a mechanism-based cross-indication rationale cannot be constructed at this stage.
From established clinical pharmacology, Saxagliptin reversibly and selectively inhibits DPP-4, the enzyme that rapidly inactivates the incretin hormones GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). By extending the half-life of these hormones, Saxagliptin potentiates glucose-dependent insulin secretion from pancreatic beta cells and suppresses inappropriate glucagon release, resulting in improved glycaemic control in type 2 diabetes mellitus.
Detailed mechanism of action data was not captured in this evidence pack (data gap DG002). Until this is resolved, any mechanistic reasoning about candidate new indications — for example, cardio-metabolic, renal, or inflammatory conditions where DPP-4 biology has been explored in the literature — would rest on inference rather than verified data. Remediation via the DrugBank API (DB06335) is required before proceeding.
Clinical Trial Evidence
Currently no related clinical trials retrieved in this evidence pack.
Literature Evidence
Currently no related literature available in this evidence pack.
UK Market Information
No marketing authorisation records were returned in this evidence pack (0 licences, status: not marketed).
Important caveat: This is likely a data collection gap rather than an accurate reflection of the UK regulatory position. Saxagliptin is authorised by the MHRA and is available in the UK as Onglyza® (saxagliptin 2.5 mg and 5 mg film-coated tablets, AstraZeneca AB) for the treatment of type 2 diabetes mellitus in adults. It is also available as a fixed-dose combination with dapagliflozin (Qtern®). MHRA licence data must be retrieved and populated in the evidence pack before evaluation proceeds.
Safety Considerations
No safety data was returned in this evidence pack. Please refer to the current Saxagliptin SmPC and the BNF (section 6.1.2 — Antidiabetic drugs) for full safety information. Of note, the SAVOR-TIMI 53 cardiovascular outcomes trial identified an increased risk of hospitalisation for heart failure with saxagliptin, which is reflected in a black-box–equivalent warning in the approved prescribing information.
Report suspected adverse reactions via the Yellow Card Scheme (https://yellowcard.mhra.gov.uk/).
Conclusion and Next Steps
Decision: Hold
Rationale: This evidence pack is critically incomplete — no TxGNN repurposing predictions have been generated, both the MHRA safety profile and the mechanism of action are absent, and the UK regulatory licence data has not been collected. A meaningful repurposing evaluation cannot be produced from the current data.
To proceed, the following is needed:
- Resolve DG001 (Blocking): Retrieve and parse the current MHRA SmPC for Saxagliptin (Onglyza®) to extract warnings, contraindications, special precautions, and drug interactions. This is a prerequisite for safety-stage screening.
- Resolve DG002 (High): Query the DrugBank API for DB06335 to populate the mechanism of action, pharmacodynamics, and target data. This is required for mechanistic plausibility analysis.
- Populate UK licence data: Retrieve MHRA marketing authorisation records (PL numbers, approved indications, dosage forms, current market status) to complete the regulatory section.
- Re-run TxGNN prediction pipeline: Once drug data are populated, re-run the knowledge graph and deep learning prediction steps to generate repurposing candidates for Saxagliptin.
- Re-generate this report: Issue a new evidence pack (v5+) incorporating the above data, then produce a full repurposing evaluation report with candidate indication, evidence tables, and safety review.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.